Introduction Ra dicut ® ( Eda ra vone ) is a medicine first developed in Japan to help patients recovering from acute ischemic stroke. It works by reducing harmful free ra dicals and has been used since 2001 to manage stroke-related neurological symptoms. 1 Because of its protective effect on nerve cells, Japanese doctors suggested that it might also help people with ALS/MND. This led to clinical trials by Mitsubishi Tanabe Pharma, the makers of Ra dicut . 1 ,2 Why RA DICUT Access Is Limited Globally RA DICUT represents one of the few disease modifying the ra pies for Amyotrophic Late ra l Sclerosis (ALS), a progressive neurodegene ra tive disease. 3 However, despite its potential, access to RA DICUT remains highly variable worldwide for seve ra l reasons: Regulatory approvals are f ra gmented. Although Ra dicut has been approved for ALS in countrie...